Axon Enterprise, Inc $AXON Shares Bought by First Horizon Advisors Inc.

First Horizon Advisors Inc. grew its position in Axon Enterprise, Inc (NASDAQ:AXON) by 15.5% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 716 shares of the biotechnology company’s stock after acquiring an additional 96 shares during the period. First Horizon Advisors Inc.’s holdings in Axon Enterprise were worth $593,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. Integrity Wealth Solutions LLC purchased a new position in shares of Axon Enterprise in the 2nd quarter valued at about $219,000. Cassaday & Co Wealth Management LLC boosted its position in Axon Enterprise by 8.9% during the second quarter. Cassaday & Co Wealth Management LLC now owns 465 shares of the biotechnology company’s stock worth $385,000 after purchasing an additional 38 shares in the last quarter. Milestone Asset Management LLC acquired a new stake in Axon Enterprise in the second quarter valued at approximately $3,953,000. NewSquare Capital LLC grew its holdings in Axon Enterprise by 96.2% in the second quarter. NewSquare Capital LLC now owns 51 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 25 shares during the period. Finally, Bridgewater Advisors Inc. increased its position in shares of Axon Enterprise by 3.3% in the second quarter. Bridgewater Advisors Inc. now owns 853 shares of the biotechnology company’s stock valued at $706,000 after buying an additional 27 shares in the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $587.14 on Friday. The firm has a 50-day simple moving average of $722.51 and a 200-day simple moving average of $734.37. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $46.09 billion, a price-to-earnings ratio of 144.97, a price-to-earnings-growth ratio of 29.49 and a beta of 1.45. Axon Enterprise, Inc has a 52 week low of $462.81 and a 52 week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.46). The business had revenue of $710.64 million for the quarter, compared to analysts’ expectations of $704.83 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm’s revenue was up 30.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.45 EPS. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AXON has been the topic of a number of research analyst reports. Barclays dropped their price target on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a research note on Thursday. JMP Securities reaffirmed a “market outperform” rating and set a $825.00 price objective on shares of Axon Enterprise in a report on Monday, September 29th. Cowen reiterated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday. Weiss Ratings restated a “hold (c)” rating on shares of Axon Enterprise in a research report on Wednesday, October 8th. Finally, Zacks Research lowered shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 2nd. Fifteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $810.71.

Insider Transactions at Axon Enterprise

In related news, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $713.74, for a total transaction of $7,137,400.00. Following the transaction, the chief executive officer owned 3,033,982 shares in the company, valued at approximately $2,165,474,312.68. This trade represents a 0.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jeri Williams sold 100 shares of the business’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $752.54, for a total value of $75,254.00. Following the transaction, the director directly owned 1,416 shares in the company, valued at $1,065,596.64. This trade represents a 6.60% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 59,932 shares of company stock valued at $45,115,616. 4.40% of the stock is currently owned by company insiders.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.